Literature DB >> 32166631

Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration.

S Richard Dunham1, Robert Schmidt2, David B Clifford3.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a viral disease of the brain associated with immunodeficiency, immune suppressing medications, and malignancy. In the absence of effective anti-viral therapy for the causative JC virus, immune restoration has emerged as the critical therapeutic alternative. The evolving treatment of PML (and other rare JC virus-associated neurologic syndromes) requires consideration of baseline immune functioning and comorbid diseases while selecting from a number of therapeutic options to restore an effective immune response. This review focuses on the current options for management of PML in typical situations where this disease presents, including several where immune restoration is a standard therapeutic approach such as in PML associated with HIV/AIDS and in multiple sclerosis associated with natalizumab. Other circumstances in which PML occurs including associated with primary immunodeficiencies, malignancies, and transplants present greater challenges to immune reconstitution, but emerging concepts may enhance therapeutic options for these situations. Particular attention is focused on recent experience with checkpoint inhibitors, guidance for MS drug discontinuation, and strategies to monitor and facilitate immune restoration.

Entities:  

Keywords:  PML; Progressive multifocal leukoencephalopathy; therapy.; treatment

Mesh:

Substances:

Year:  2020        PMID: 32166631      PMCID: PMC7641288          DOI: 10.1007/s13311-020-00848-z

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


  94 in total

1.  Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

Authors:  Carmen Bozic; Sandra Richman; Tatiana Plavina; Amy Natarajan; James V Scanlon; Meena Subramanyam; Alfred Sandrock; Gary Bloomgren
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

2.  Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.

Authors:  Grant A Hill-Cawthorne; Tom Button; Orla Tuohy; Joanne L Jones; Karen May; Jennifer Somerfield; Alison Green; Gavin Giovannoni; D Alastair S Compston; Michael T Fahey; Alasdair J Coles
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-11-05       Impact factor: 10.154

3.  No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.

Authors:  Doriana Landi; Nicola De Rossi; Sara Zagaglia; Cristina Scarpazza; Luca Prosperini; Maria Albanese; Fabio Buttari; Francesco Mori; Girolama Alessandra Marfia; Maria Pia Sormani; Ruggero Capra; Diego Centonze
Journal:  Neurology       Date:  2017-02-22       Impact factor: 9.910

4.  IL-7 knocks the socs off chronic viral infection.

Authors:  Ian A Parish; Susan M Kaech
Journal:  Cell       Date:  2011-02-18       Impact factor: 41.582

5.  Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?

Authors:  Cristina Scarpazza; Luca Prosperini; Chiara R Mancinelli; Nicola De Rossi; Alessandra Lugaresi; Marco Capobianco; Lucia Moiola; Paola Naldi; Luisa Imberti; Simonetta Gerevini; Ruggero Capra
Journal:  J Neurol Sci       Date:  2017-05-12       Impact factor: 3.181

6.  To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy.

Authors:  Cristina Scarpazza; Luca Prosperini; Nicola De Rossi; Lucia Moiola; Maria Pia Sormani; Simonetta Gerevini; Ruggero Capra
Journal:  Ann Neurol       Date:  2017-10-31       Impact factor: 10.422

7.  Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.

Authors:  Collin M Spencer; Elizabeth C Crabtree-Hartman; Klaus Lehmann-Horn; Bruce A C Cree; Scott S Zamvil
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-02-12

8.  Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?

Authors:  Marc Pawlitzki; Tilman Schneider-Hohendorf; Leoni Rolfes; Sven G Meuth; Heinz Wiendl; Nicholas Schwab; Oliver M Grauer
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-10-09

9.  Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency.

Authors:  Clemens Küpper; Johanna Heinrich; Katharina Kamm; Veit Bücklein; Simon Rothenfusser; Andreas Straube
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-10-09

10.  CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection.

Authors:  Hassen S Wollebo; Anna Bellizzi; Rafal Kaminski; Wenhui Hu; Martyn K White; Kamel Khalili
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

View more
  4 in total

1.  Adipocyte Plasma Membrane Protein (APMAP) promotes JC Virus (JCPyV) infection in human glial cells.

Authors:  Sheila A Haley; Bethany A O'Hara; Walter J Atwood
Journal:  Virology       Date:  2020-06-07       Impact factor: 3.616

2.  Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy.

Authors:  Franziska Hopfner; Nora Möhn; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Jens Gottlieb; Rainer Blasczyk; Nima Mahmoudi; Kaweh Pars; Ortwin Adams; Martin Stangel; Mike P Wattjes; Günter Höglinger; Thomas Skripuletz
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-17

3.  It was 40 Years Ago Today: AIDS and the Brain.

Authors:  Eelco F M Wijdicks
Journal:  Neurocrit Care       Date:  2022-03-01       Impact factor: 3.532

4.  BK virus-specific T cells for immunotherapy of progressive multifocal leukoencephalopathy: an open-label, single-cohort pilot study.

Authors:  Irene Cortese; Erin S Beck; Omar Al-Louzi; Joan Ohayon; Frances Andrada; Ikesinachi Osuorah; Jenifer Dwyer; B Jeanne Billioux; Nigar Dargah-Zada; Matthew K Schindler; Kyle Binder; Lauren Reoma; Gina Norato; Yoshimi Enose-Akahata; Bryan R Smith; Maria Chiara Monaco; Eugene O Major; Steven Jacobson; David Stroncek; Steven Highfill; Sandhya Panch; Daniel S Reich; John Barrett; Avindra Nath; Pawel Muranski
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 59.935

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.